CAI Caris Life Sciences, Inc.
Services-Medical Laboratories · Nasdaq · SEC CIK 2019410 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY61.5%
TTM net income YoY151.4%
TTM EPS YoY125.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin13.4%
Net margin9.2%
FCF margin2.8%
EBITDA margin15.5%
Returns
ROE17.2%
ROA8.6%
ROIC (approx.)24.3%
Asset turnover0.94x
Leverage & solvency
Liabilities / assets49.1%
Debt / equity0.61x
Current ratio6.71x
Interest coverage3.28x
Cash quality & payout
Operating cash flow / net income0.87x
Accruals ratio1.1%
Payout ratio—
Capex / revenue5.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $812.03M | $412.26M |
| R&D expense | $101.58M | $113.92M |
| SG&A expense | $224.97M | $169.39M |
| Operating income | $45.11M | -$257.12M |
| Interest expense | $56.85M | $50.02M |
| Pretax income | -$68.09M | -$281.89M |
| Income tax | $0 | $0 |
| Net income | -$68.09M | -$281.89M |
| EBITDA | $67.73M | -$208.21M |
| EPS (basic) | -3.22 | -10.66 |
| EPS (diluted) | -3.22 | -10.66 |
| Weighted avg. shares (diluted) | 167.21M | 35.50M |
| Balance sheet | ||
| Cash & equivalents | $796.27M | $63.95M |
| Short-term investments | $2.29M | $2.20M |
| Receivables | $112.14M | $88.24M |
| Current assets | $997.80M | $215.73M |
| PP&E, net | $63.17M | $67.82M |
| Goodwill | $19.34M | $19.34M |
| Total assets | $1.13B | $343.73M |
| Current liabilities | $127.14M | $165.42M |
| Short-term debt | $169,000 | $60.09M |
| Long-term debt | $378.82M | $319.44M |
| Total debt | $378.99M | $379.53M |
| Total liabilities | $548.36M | $620.92M |
| Shareholders' equity | $577.31M | -$2.50B |
| Net debt | -$417.28M | $315.58M |
| Shares outstanding | 282.53M | 36.50M |
| Cash flow statement | ||
| Operating cash flow | $83.16M | -$245.20M |
| Capital expenditure | $16.26M | $8.44M |
| Free cash flow | $66.89M | -$253.64M |
| Investing cash flow | -$16.26M | $52.93M |
| Financing cash flow | $664.99M | $200.29M |
| Depreciation & amortization | $22.61M | $48.91M |
| Stock-based compensation | $70.01M | $18.64M |
| Share buybacks | $113,000 | $0 |
Free plan shows the latest 2 periods; Pro shows all 3 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.